Skip to Main Content

Author Details

Peter S Hammerman
Novartis Institutes for BioMedical Research
1996
108
64
PMIDPaper TitleJournal TitlePublished Year
37603596Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance.Cancer Res2023
37603596Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance.Cancer Res2023
34615655Sex-Biased <i>ZRSR2</i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.Cancer Discov2022
34615655Sex-Biased <i>ZRSR2</i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.Cancer Discov2022
33151910Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade.J Clin Invest2021
34142094ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer.Nat Cancer2021
33504557Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.Cancer Res2021
33046519Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.Clin Cancer Res2021
33151910Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade.J Clin Invest2021
33355204LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.Clin Cancer Res2021
33504557Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.Cancer Res2021
34142094ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer.Nat Cancer2021
33046519Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.Clin Cancer Res2021
33355204LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.Clin Cancer Res2021
31883968CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer.Cancer Cell2020
31744829 <i>In Vivo</i> Epigenetic CRISPR Screen Identifies <i>Asf1a</i> as an Immunotherapeutic Target in <i>Kras</i>-Mutant Lung Adenocarcinoma.Cancer Discov2020
32076487Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR.Oncotarget2020
31883968CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer.Cancer Cell2020
32076487Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR.Oncotarget2020
31744829 <i>In Vivo</i> Epigenetic CRISPR Screen Identifies <i>Asf1a</i> as an Immunotherapeutic Target in <i>Kras</i>-Mutant Lung Adenocarcinoma.Cancer Discov2020
30564890Identification and characterization of an alternative cancer-derived PD-L1 splice variant.Cancer Immunol Immunother2019
31695192Author Correction: LKB1 loss links serine metabolism to DNA methylation and tumorigenesis.Nature2019
30564890Identification and characterization of an alternative cancer-derived PD-L1 splice variant.Cancer Immunol Immunother2019
31068384SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.Mol Cancer Ther2019
30728077Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity.J Immunother Cancer2019
31324888Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.Oncogene2019
31439712Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.Mol Cancer Ther2019
31295753Oral keratosis of unknown significance shares genomic overlap with oral dysplasia.Oral Dis2019
31695192Author Correction: LKB1 loss links serine metabolism to DNA methylation and tumorigenesis.Nature2019
31439712Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.Mol Cancer Ther2019
31324888Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.Oncogene2019
31295753Oral keratosis of unknown significance shares genomic overlap with oral dysplasia.Oral Dis2019
31068384SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.Mol Cancer Ther2019
30728077Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity.J Immunother Cancer2019
28969885Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma.Int J Oral Maxillofac Surg2018
28969885Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma.Int J Oral Maxillofac Surg2018
29054992Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.Cancer Discov2018
30250255Author Correction: EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.Nature2018
30150660Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.Nat Genet2018
30282824Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.JCI Insight2018
30087114BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in <i>Kras</i>-Mutant Non-Small Cell Lung Cancer.Cancer Immunol Res2018
29760044NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.Cancer Res2018
29259014ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase Inhibitors.Cancer Res2018
29654068RAS-MAPK Reactivation Facilitates Acquired Resistance in <i>FGFR1</i>-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.Mol Cancer Ther2018
29276047Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors.Cell Chem Biol2018
30150660Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.Nat Genet2018
30250255Author Correction: EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.Nature2018
30087114BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in <i>Kras</i>-Mutant Non-Small Cell Lung Cancer.Cancer Immunol Res2018
30282824Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.JCI Insight2018
29654068RAS-MAPK Reactivation Facilitates Acquired Resistance in <i>FGFR1</i>-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.Mol Cancer Ther2018
  • 1 - 50 of 216

Recommended Authors

Andrew Goodspeed
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 0
Yang Shao
Nanjing Geneseeq Technology Inc.
Career Start Year 2012
Number of shared co-authors 1
Yisong Wang
Lombardi Comprehensive Cancer Center, Georgetown University
Career Start Year 2010
Number of shared co-authors 0
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Larissa A Pikor
Ottawa Hospital Research Institute
Career Start Year 2010
Number of shared co-authors 1
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
Vibha Raghavan
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2009
Number of shared co-authors 1
Caroline E McCoach
UCSF Helen Diller Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 6
Neil E Bhola
Zai Lab (US) LLC
Career Start Year 2006
Number of shared co-authors 11
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Career Start Year 2006
Number of shared co-authors 49
Pichai Raman
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Career Start Year 2006
Number of shared co-authors 12
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 9
Ming Li
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2003
Number of shared co-authors 2
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 3
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 0
Trever G Bivona
University of California san francisco
Career Start Year 2002
Number of shared co-authors 20
Benjamin Solomon
Peter MacCallum Cancer Centre
Career Start Year 2000
Number of shared co-authors 12
Collin M Blakely
University of California san francisco
Career Start Year 1998
Number of shared co-authors 6
Anthony J Iafrate
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 25
Charles Swanton
Francis Crick Institute
Career Start Year 1997
Number of shared co-authors 10
Siraj M Ali
Foundation Medicine
Career Start Year 1995
Number of shared co-authors 12
Timothy A Chan
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 49
Michael Peyton
Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center
Career Start Year 1994
Number of shared co-authors 15
Ultan McDermott
Wellcome Sanger Institute
Career Start Year 1993
Number of shared co-authors 21
Tatsuhiro Shibata
Kurume University School of Medicine
Career Start Year 1993
Number of shared co-authors 2
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 6
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 9
David S Schrump
Center for Cancer Research, National Cancer Institute
Career Start Year 1988
Number of shared co-authors 1
Marc Ladanyi
Memorial Sloan Kettering Cancer Center
Career Start Year 1984
Number of shared co-authors 33
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 11

Collaborators

Matthew Meyerson
Broad Institute
Co-authored papers 18
Pasi A J??nne
Dana-Farber Cancer Institute
Co-authored papers 16
Nathanael S Gray
Harvard Medical School
Co-authored papers 13
Adam J Bass
Co-authored papers 12
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 9
Robert I Haddad
Dana-Farber Cancer Institute, Harvard Medical School
Co-authored papers 9
David Neil Hayes
Center for Cancer Research, University of Tennessee Health Science Center
Co-authored papers 8
Levi A Garraway
Broad Institute of Harvard and MIT
Co-authored papers 7
Elena Ivanova
Dana-Farber Cancer Institute
Co-authored papers 7
Jennifer R Grandis
University of California san francisco
Co-authored papers 6
Robert T Jones
Co-authored papers 6
Rachel G Liao
Co-authored papers 6
Michael S Lawrence
Co-authored papers 6
Matthew D Wilkerson
Uniformed Services University of the Health Sciences
Co-authored papers 6
Chandra Sekhar Pedamallu
Broad Institute
Co-authored papers 6
Raphael Bueno
Co-authored papers 5
Trevor J Pugh
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 5
Ruben Dries
Boston University School of Medicine
Co-authored papers 5
Giordano Caponigro
Co-authored papers 5
Nabeel Bardeesy
Massachusetts General Hospital
Co-authored papers 5
Petar Stojanov
Co-authored papers 4
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 4
James E Bradner
Co-authored papers 4
Andrey Sivachenko
Cystic Fibrosis Foundation
Co-authored papers 4
Scott L Carter
Co-authored papers 4
Catherine J Wu
Co-authored papers 3
Jaegil Kim
Co-authored papers 3
Alex H Ramos
Co-authored papers 3
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 3
Pablo Tamayo
University of California San Diego
Co-authored papers 3
Release 1.2